The function and therapeutic targeting of anaplastic lymphoma kinase (ALK) in non-small cell lung cancer (NSCLC)
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
The function and therapeutic targeting of anaplastic lymphoma kinase (ALK) in non-small cell lung cancer (NSCLC)
Authors
Keywords
Lung cancer, Anaplastic lymphoma kinase, ALK, Molecular-targeted therapy, Cell signalling
Journal
Molecular Cancer
Volume 17, Issue 1, Pages -
Publisher
Springer Nature
Online
2018-02-15
DOI
10.1186/s12943-018-0810-4
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Efficacy of alectinib in central nervous system metastases in crizotinib-resistant ALK -positive non–small-cell lung cancer: Comparison of RECIST 1.1 and RANO-HGG criteria
- (2017) Leena Gandhi et al. EUROPEAN JOURNAL OF CANCER
- Discovery of N -(5-((5-chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidin-2-yl)amino)-4-methoxy-2-(4-methyl-1,4-diazepan-1-yl)phenyl)acrylamide (CHMFL-ALK/EGFR-050) as a potent ALK/EGFR dual kinase inhibitor capable of overcoming a variety of ALK/EGFR associated drug resistant mutants in NSCLC
- (2017) Yongfei Chen et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Heat shock protein antagonists in early stage clinical trials for NSCLC
- (2017) Lizza E.L. Hendriks et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Brigatinib in Patients With Crizotinib-Refractory Anaplastic Lymphoma Kinase–Positive Non–Small-Cell Lung Cancer: A Randomized, Multicenter Phase II Trial
- (2017) Dong-Wan Kim et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase I Results from a Study of Crizotinib in Combination with Erlotinib in Patients with Advanced Nonsquamous Non–Small Cell Lung Cancer
- (2017) Sai-Hong Ignatius Ou et al. Journal of Thoracic Oncology
- ASCEND-8: A Randomized Phase 1 Study of Ceritinib, 450 mg or 600 mg, Taken with a Low-Fat Meal versus 750 mg in Fasted State in Patients with Anaplastic Lymphoma Kinase ( ALK )-Rearranged Metastatic Non–Small Cell Lung Cancer (NSCLC)
- (2017) Byoung Chul Cho et al. Journal of Thoracic Oncology
- Alectinib versus Crizotinib in Untreated ALK-Positive Non–Small-Cell Lung Cancer
- (2017) Solange Peters et al. NEW ENGLAND JOURNAL OF MEDICINE
- Targeting ALK: Precision Medicine Takes on Drug Resistance
- (2017) Jessica J. Lin et al. Cancer Discovery
- Spotlight on ceritinib in the treatment of ALK+ NSCLC: design, development and place in therapy
- (2017) Mariacarmela Santarpia et al. Drug Design Development and Therapy
- Performance of a RT-PCR Assay in Comparison to FISH and Immunohistochemistry for the Detection of ALK in Non-Small Cell Lung Cancer
- (2017) David Hout et al. Cancers
- Lung Cancer: Understanding Its Molecular Pathology and the 2015 WHO Classification
- (2017) Kentaro Inamura Frontiers in Oncology
- Systemic Therapy for Stage IV Non–Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update Summary
- (2017) Nasser Hanna et al. Journal of Oncology Practice
- ALK and IGF-1R as independent targets in crizotinib resistant lung cancer
- (2017) Christabel Wilson et al. Scientific Reports
- Detection of known and novel ALK fusion transcripts in lung cancer patients using next-generation sequencing approaches
- (2017) Julie A. Vendrell et al. Scientific Reports
- Precision medicine in NSCLC and pathology: how does ALK fit in the pathway?
- (2016) K. M. Kerr et al. ANNALS OF ONCOLOGY
- The Potent ALK Inhibitor Brigatinib (AP26113) Overcomes Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in Preclinical Models
- (2016) Sen Zhang et al. CLINICAL CANCER RESEARCH
- Combined Pan-HER and ALK/ROS1/MET Inhibition with Dacomitinib and Crizotinib in Advanced Non–Small Cell Lung Cancer: Results of a Phase I Study
- (2016) Pasi A. Jänne et al. Journal of Thoracic Oncology
- Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F
- (2016) Alice T. Shaw et al. NEW ENGLAND JOURNAL OF MEDICINE
- Coupling an EML4-ALK-centric interactome with RNA interference identifies sensitizers to ALK inhibitors
- (2016) G. Zhang et al. Science Signaling
- Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer
- (2016) J. F. Gainor et al. Cancer Discovery
- Coupling an EML4-ALK-centric interactome with RNA interference identifies sensitizers to ALK inhibitors
- (2016) G. Zhang et al. Science Signaling
- Elucidation of Resistance Mechanisms to Second-Generation ALK Inhibitors Alectinib and Ceritinib in Non–Small Cell Lung Cancer Cells
- (2016) Xuyuan Dong et al. NEOPLASIA
- P-glycoprotein Mediates Ceritinib Resistance in Anaplastic Lymphoma Kinase-rearranged Non-small Cell Lung Cancer
- (2016) Ryohei Katayama et al. EBioMedicine
- Insights into brain metastasis in patients with ALK+ lung cancer: is the brain truly a sanctuary?
- (2015) Gouji Toyokawa et al. CANCER AND METASTASIS REVIEWS
- Progression-Free and Overall Survival in ALK-Positive NSCLC Patients Treated with Sequential Crizotinib and Ceritinib
- (2015) J. F. Gainor et al. CLINICAL CANCER RESEARCH
- Therapeutic Targeting of Anaplastic Lymphoma Kinase in Lung Cancer: A Paradigm for Precision Cancer Medicine
- (2015) R. Katayama et al. CLINICAL CANCER RESEARCH
- I1171 missense mutation (particularly I1171N) is a common resistance mutation in ALK-positive NSCLC patients who have progressive disease while on alectinib and is sensitive to ceritinib
- (2015) Sai-Hong Ignatius Ou et al. LUNG CANCER
- EMT is associated with, but does not drive resistance to ALK inhibitors among EML4-ALK non-small cell lung cancer
- (2015) Arjan Gower et al. Molecular Oncology
- Augmentor α and β (FAM150) are ligands of the receptor tyrosine kinases ALK and LTK: Hierarchy and specificity of ligand–receptor interactions
- (2015) Andrey V. Reshetnyak et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Heparin is an activating ligand of the orphan receptor tyrosine kinase ALK
- (2015) Phillip B. Murray et al. Science Signaling
- FAM150A and FAM150B are activating ligands for anaplastic lymphoma kinase
- (2015) Jikui Guan et al. eLife
- Heparin is an activating ligand of the orphan receptor tyrosine kinase ALK
- (2015) Phillip B. Murray et al. Science Signaling
- Evaluation of EML4-ALK Fusion Proteins in Non–Small Cell Lung Cancer Using Small Molecule Inhibitors
- (2015) Yongjun Li et al. NEOPLASIA
- Two Novel ALK Mutations Mediate Acquired Resistance to the Next-Generation ALK Inhibitor Alectinib
- (2014) R. Katayama et al. CLINICAL CANCER RESEARCH
- Cost Effectiveness ofEML4-ALKFusion Testing and First-Line Crizotinib Treatment for Patients With AdvancedALK-Positive Non–Small-Cell Lung Cancer
- (2014) Sandjar Djalalov et al. JOURNAL OF CLINICAL ONCOLOGY
- Next-Generation Sequencing Reveals a Novel NSCLC ALK F1174V Mutation and Confirms ALK G1202R Mutation Confers High-Level Resistance to Alectinib (CH5424802/RO5424802) in ALK-Rearranged NSCLC Patients Who Progressed on Crizotinib
- (2014) Sai-Hong Ignatius Ou et al. Journal of Thoracic Oncology
- Secondary Mutations at I1171 in the ALK Gene Confer Resistance to Both Crizotinib and Alectinib
- (2014) Gouji Toyokawa et al. Journal of Thoracic Oncology
- Crizotinib Can Overcome Acquired Resistance to CH5424802: Is Amplification of the MET Gene a Key Factor?
- (2014) Toyokawa Gouji et al. Journal of Thoracic Oncology
- Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study
- (2014) Shirish M Gadgeel et al. LANCET ONCOLOGY
- Comprehensive molecular profiling of lung adenocarcinoma
- (2014) Eric A. Collisson et al. NATURE
- In vivo engineering of oncogenic chromosomal rearrangements with the CRISPR/Cas9 system
- (2014) Danilo Maddalo et al. NATURE
- Rationale for co-targeting IGF-1R and ALK in ALK fusion–positive lung cancer
- (2014) Christine M Lovly et al. NATURE MEDICINE
- First-Line Crizotinib versus Chemotherapy in ALK-Positive Lung Cancer
- (2014) Benjamin J. Solomon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Patient-derived models of acquired resistance can identify effective drug combinations for cancer
- (2014) Adam S. Crystal et al. SCIENCE
- The Cost-Effectiveness of Second-Line Crizotinib in Eml4-Alk Rearranged Advanced Non-Small Cell Lung Cancer
- (2014) S. Djalalov et al. VALUE IN HEALTH
- The ALK Inhibitor Ceritinib Overcomes Crizotinib Resistance in Non-Small Cell Lung Cancer
- (2014) L. Friboulet et al. Cancer Discovery
- A Multicenter Phase II Study of Ganetespib Monotherapy in Patients with Genotypically Defined Advanced Non-Small Cell Lung Cancer
- (2013) M. A. Socinski et al. CLINICAL CANCER RESEARCH
- Targeting ALK in patients with advanced Non Small Cell Lung Cancer: Biology, diagnostic and therapeutic options
- (2013) Chiara Lazzari et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Crizotinib versus Chemotherapy in Advanced ALK-Positive Lung Cancer
- (2013) Alice T. Shaw et al. NEW ENGLAND JOURNAL OF MEDICINE
- Targeted Inhibition of the Molecular Chaperone Hsp90 Overcomes ALK Inhibitor Resistance in Non–Small Cell Lung Cancer
- (2013) Jim Sang et al. Cancer Discovery
- Combined effect of ALK and MEK inhibitors in EML4–ALK-positive non-small-cell lung cancer cells
- (2012) J Tanizaki et al. BRITISH JOURNAL OF CANCER
- Mechanisms of Resistance to Crizotinib in Patients withALKGene Rearranged Non–Small Cell Lung Cancer
- (2012) Robert C. Doebele et al. CLINICAL CANCER RESEARCH
- Activation of HER Family Signaling as a Mechanism of Acquired Resistance to ALK Inhibitors in EML4-ALK-Positive Non-Small Cell Lung Cancer
- (2012) J. Tanizaki et al. CLINICAL CANCER RESEARCH
- Immunohistochemical screening for anaplastic lymphoma kinase (ALK) rearrangement in advanced non-small cell lung cancer patients
- (2012) Heae Surng Park et al. LUNG CANCER
- Crizotinib-Resistant NPM-ALK Mutants Confer Differential Sensitivity to Unrelated Alk Inhibitors
- (2012) M. Ceccon et al. MOLECULAR CANCER RESEARCH
- Mechanisms of Acquired Crizotinib Resistance in ALK-Rearranged Lung Cancers
- (2012) R. Katayama et al. Science Translational Medicine
- CH5424802, a Selective ALK Inhibitor Capable of Blocking the Resistant Gatekeeper Mutant
- (2011) Hiroshi Sakamoto et al. CANCER CELL
- A Novel ALK Secondary Mutation and EGFR Signaling Cause Resistance to ALK Kinase Inhibitors
- (2011) T. Sasaki et al. CANCER RESEARCH
- ALK Mutations Conferring Differential Resistance to Structurally Diverse ALK Inhibitors
- (2011) J. M. Heuckmann et al. CLINICAL CANCER RESEARCH
- Role of ERK-BIM and STAT3-Survivin Signaling Pathways in ALK Inhibitor-Induced Apoptosis in EML4-ALK-Positive Lung Cancer
- (2011) K. Takezawa et al. CLINICAL CANCER RESEARCH
- Targeting Oncogenic ALK: A Promising Strategy for Cancer Treatment
- (2011) E. Grande et al. MOLECULAR CANCER THERAPEUTICS
- Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK
- (2011) R. Katayama et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Inhibition of ALK, PI3K/MEK, and HSP90 in Murine Lung Adenocarcinoma Induced by EML4-ALK Fusion Oncogene
- (2010) Z. Chen et al. CANCER RESEARCH
- A Novel, Highly Sensitive Antibody Allows for the Routine Detection of ALK-Rearranged Lung Adenocarcinomas by Standard Immunohistochemistry
- (2010) M. Mino-Kenudson et al. CLINICAL CANCER RESEARCH
- EML4-ALK Mutations in Lung Cancer That Confer Resistance to ALK Inhibitors
- (2010) Young Lim Choi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
- (2010) Eunice L. Kwak et al. NEW ENGLAND JOURNAL OF MEDICINE
- Unique Clinicopathologic Features Characterize ALK-Rearranged Lung Adenocarcinoma in the Western Population
- (2009) S. J. Rodig et al. CLINICAL CANCER RESEARCH
- TP53 Mutations in Human Cancers: Origins, Consequences, and Clinical Use
- (2009) M. Olivier et al. Cold Spring Harbor Perspectives in Biology
- High incidence of DNA mutations and gene amplifications of theALKgene in advanced sporadic neuroblastoma tumours
- (2008) Helena Carén et al. BIOCHEMICAL JOURNAL
- Multiplex Reverse Transcription-PCR Screening for EML4-ALK Fusion Transcripts
- (2008) K. Takeuchi et al. CLINICAL CANCER RESEARCH
- Oncogenic mutations of ALK kinase in neuroblastoma
- (2008) Yuyan Chen et al. NATURE
- Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma
- (2008) Isabelle Janoueix-Lerosey et al. NATURE
- Activation of tyrosine kinases by mutation of the gatekeeper threonine
- (2008) Mohammad Azam et al. NATURE STRUCTURAL & MOLECULAR BIOLOGY
- A mouse model for EML4-ALK-positive lung cancer
- (2008) M. Soda et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search